TB-500: Research Overview, Mechanism of Action & Lab Supply Standards
A summary of published preclinical research on TB-500 (Thymosin Beta-4), including proposed mechanisms, study findings, purity standards for research use, and sourcing considerations for Canadian researchers.
What Is TB-500?
TB-500 is a synthetic peptide fragment corresponding to amino acids 17–23 of Thymosin Beta-4, a naturally occurring 43-amino acid protein found in high concentrations in blood platelets, wound fluid, and most tissues throughout the body. Thymosin Beta-4 was first isolated from thymic tissue and subsequently identified as a major actin-sequestering protein in non-muscle cells.
The TB-500 fragment retains the actin-binding domain of the full Thymosin Beta-4 molecule and has been investigated in preclinical models for tissue repair, angiogenesis, and anti-inflammatory activity. All published research reviewed on this page involves preclinical animal models. No peer-reviewed human clinical trials have been completed or published for TB-500 as of this writing.
Proposed Mechanisms of Action
The following mechanisms have been proposed and studied across published preclinical literature:
G-Actin Sequestration
TB-500 binds to G-actin (monomeric actin), preventing polymerization into F-actin filaments. This actin sequestration activity is central to its proposed role in promoting cell migration — a process dependent on regulated actin dynamics at the leading edge of migrating cells.
Cell Migration and Tissue Repair
Preclinical models have documented TB-500-associated increases in keratinocyte and endothelial cell migration rates. This is consistent with the compound's actin-modulating activity and has been studied in wound healing, tendon, and corneal injury contexts in rodent models.
Angiogenesis
Thymosin Beta-4 and its fragments have been studied for their role in new blood vessel formation. Research has documented upregulation of angiogenic signaling including VEGF pathway involvement, with preclinical models showing enhanced vascular density in treated tissue.
Anti-Inflammatory Activity
Multiple preclinical studies have documented Thymosin Beta-4's ability to downregulate NF-κB signaling and reduce pro-inflammatory cytokine expression. This anti-inflammatory activity appears to be independent of its actin-sequestering function and has been studied in cardiac and ocular tissue models.
Selected Published Research
The following is a selection of peer-reviewed studies available in PubMed. All studies listed involve preclinical or in vitro research. This is not a comprehensive literature review.
Goldstein AL, Hannappel E, Kleinman HK. — Trends in Molecular Medicine, 2005
Reviews the dual function of Thymosin Beta-4 as both an actin-sequestering protein and a tissue repair mediator, with discussion of wound healing and anti-inflammatory activity across preclinical models.
Smart N, et al. — Nature, 2011
Rodent study demonstrating that Thymosin Beta-4 treatment following myocardial infarction activated epicardial progenitor cells and contributed to cardiomyocyte regeneration, suggesting potential cardiac repair applications.
Philp D, et al. — Journal of Investigative Dermatology Symposium Proceedings, 2004
Examined Thymosin Beta-4 in dermal wound healing models, documenting accelerated wound closure and increased keratinocyte migration in treated versus control groups in vitro and in vivo.
Sosne G, et al. — Expert Opinion on Biological Therapy, 2012
Reviews preclinical research on Thymosin Beta-4 in ocular tissue models, including corneal wound repair, anti-inflammatory activity, and potential neuroprotective effects in retinal tissue.
Purity Standards for Research Use
When procuring TB-500 for laboratory research, purity and identity verification are the two most critical quality parameters:
HPLC Purity Analysis
High-performance liquid chromatography confirms compound purity by separating TB-500 from degradation products and synthesis impurities. Research-grade TB-500 should meet ≥99%+ purity by HPLC — the standard expected in published preclinical studies.
Mass Spectrometry (Identity)
MS verifies molecular weight and fragmentation pattern, confirming the compound is TB-500 and not a structurally similar substitute or mislabeled product. Identity confirmation by MS is distinct from purity testing and both are required for research-grade procurement.
Endotoxin Testing
Bacterial endotoxin testing (LAL method) is critical for in vivo research use. Endotoxin contamination confounds experimental results in animal models. Research-grade TB-500 intended for injection studies requires endotoxin verification.
Certificate of Analysis (COA)
A batch-specific COA documents HPLC result, MS data, endotoxin level, appearance, and storage conditions for each specific lot. Institutions require batch-specific COAs for procurement records — generic documents reused across lots are not acceptable.
Sourcing TB-500 in Canada
Researchers in Canada have historically sourced TB-500 from US-based suppliers, introducing customs exposure, shipping delays, and inconsistent documentation standards. A domestic Canadian source with full third-party testing removes these variables from the procurement process.
ACCUTIDE Research Supply provides TB-500 tested to ≥99%+ HPLC purity with batch-specific COA documentation. All material is lyophilized for long-term stability and ships Canada-wide.
TB-500 — Canadian Research Supply
HPLC tested · COA every batch · Ships Canada-wide · RUO
Often Researched With
Compounds frequently co-investigated alongside Tb-500 in preclinical research literature.
Research Use Only Disclaimer: All information on this page is provided for scientific research and educational purposes only. TB-500 supplied by ACCUTIDE Research Supply is strictly for laboratory and research use (RUO). It is not intended for human or animal consumption, therapeutic use, or any application outside of controlled research settings. All published studies referenced are preclinical or in vitro research. Findings must not be extrapolated to human use.